Zydus Cadila seeks regulator nod for clinical trials on Covid-19 therapy

Company says product helps treating mild coronavirus patients and reduces hospitalisation.

Cadila Healthcare has sought permission from India’s drugs regulator for starting the next phase of human clinical trials for its biological therapy to treat mild Covid-19 cases.

The company on Thursday said that the therapy named ZRC-3308, which is a cocktail of two SARS-CoV-2-neutralising monoclonal antibodies (mAbs), targets SARS-CoV-2 spike protein. It significantly reduces viral load in mild patients and their rate of hospitalisation, said the company after seeking permission from Drugs Controller General of India (DCGI) for phase 1 to 3 trials.

Zydus said treatments similar to its product have received emergency use authorisation in mild Covid-19 patients in